Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
Global Animal Model for Testing market was valued at USD 2,382 million in 2024 and is projected to reach USD 3,513 million by 2031, exhibiting a CAGR of 5.8% during the forecast period.
Animal models are living, non-human animals used in the research and investigation of human disease. They are essential tools for understanding disease pathology and for the development and safety assessment of novel therapeutics and vaccines, providing critical preclinical data without the initial risks of human trials. The utility of these models is rooted in the vast biological commonalities between humans and other mammals. This is evidenced by the fact that approximately 90% of veterinary drugs used to treat animals are identical or very similar to those used to treat humans, highlighting the translational relevance.
The market's steady growth is primarily driven by the robust and expanding research and development pipelines within the pharmaceutical and biotechnology sectors. The rise in the global prevalence of chronic and complex diseases, particularly in areas like oncology, neurology, and immunology, necessitates the use of sophisticated animal models for effective drug discovery. While this growth is significant, it is tempered by increasing ethical scrutiny and the high costs associated with developing advanced genetically engineered models. Nevertheless, key players such as Charles River Laboratories, The Jackson Laboratory, and Taconic Biosciences continue to innovate, providing a wide range of models that are critical for advancing biomedical science.
Rising Demand for Personalized Medicine and Biologics
The increasing focus on developing personalized medical treatments and complex biologic drugs, such as monoclonal antibodies and gene therapies, is a primary driver for the animal model market. These advanced therapies require rigorous safety and efficacy testing in biologically relevant systems before human trials. The global biologics market is projected to grow significantly, necessitating a corresponding increase in the use of sophisticated animal models, particularly genetically engineered mice and humanized models, to accurately predict human responses.
Government and Private Funding for Biomedical Research
Sustained investment from government bodies like the National Institutes of Health (NIH) and private pharmaceutical R&D is a critical driver. Increased funding for research into chronic diseases such as cancer, neurological disorders, and metabolic diseases directly fuels demand for appropriate animal models. This financial support enables the development of more specific and refined models, accelerating the pace of discovery.
➤ The consistent high failure rate of drugs in clinical phases underscores the indispensable role of predictive animal testing in de-risking drug development pipelines.
Furthermore, the expanding contract research organization (CRO) sector relies heavily on animal models to offer preclinical services to pharmaceutical and biotech companies, creating a stable, outsourced demand stream that propels market growth.
MARKET CHALLENGES
High Costs and Ethical Concerns
The development, breeding, and maintenance of animal models, especially genetically modified organisms, involve substantial financial investment. Furthermore, the industry faces persistent ethical scrutiny and stringent regulatory oversight regarding animal welfare, leading to complex compliance requirements and potential reputational risks for companies.
Other Challenges
Scientific and Technical Limitations
Despite advancements, the biological differences between animals and humans can lead to misleading results, causing drug candidates that are safe and effective in animals to fail in human clinical trials. This limited translational predictability remains a significant scientific hurdle.
Stringent Regulatory Frameworks
Globally, regulations like the Animal Welfare Act in the US and Directive 2010/63/EU in Europe mandate the ethical use of animals and the application of the 3Rs (Replacement, Reduction, Refinement), increasing the complexity and cost of conducting animal-based research.
Growth of Alternative Technologies
The rapid development and adoption of alternative testing methods, such as in vitro cell cultures, organ-on-a-chip technologies, and sophisticated computer modeling, pose a significant restraint to the animal model market. These alternatives are increasingly viewed as more ethical, sometimes faster, and potentially more human-relevant for specific applications, leading some research funding to be diverted away from traditional animal testing.
Logistical Complexities in Model Development
The creation and maintenance of specific pathogen-free (SPF) facilities and the management of complex genetically engineered model colonies require specialized infrastructure and expertise. These logistical hurdles can limit the scalability for providers and increase lead times for researchers, acting as a restraint on market expansion.
Advancements in Genetic Engineering Technologies
The advent of powerful gene-editing tools like CRISPR-Cas9 has revolutionized the creation of precise and complex animal models. This technology allows for the faster and more cost-effective development of models that accurately mimic human diseases, opening vast opportunities for providers specializing in custom genetically engineered models, particularly for oncology and rare genetic disorders.
Expansion in Emerging Markets
Growing pharmaceutical and biotechnology industries in emerging economies across Asia-Pacific and Latin America present significant growth opportunities. Increasing R&D expenditure, rising prevalence of diseases, and improving research infrastructure in these regions are driving the demand for animal models, encouraging global providers to expand their presence.
Humanized Animal Models for Immunotherapy
The booming field of immunotherapy, especially for cancer treatment, relies on humanized mouse models that possess a functional human immune system. The critical need to test immunotherapies in a relevant in vivo context creates a high-value, specialized niche with strong growth potential for model providers.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Mice are the predominant animal model category due to their genetic similarity to humans, short reproductive cycles, and the extensive availability of well-characterized genetic variants. The widespread adoption of mice is driven by the sophistication of genetic engineering technologies, which allow for the creation of highly specific disease models for complex conditions like cancer and neurological disorders. Rats also hold significant importance, particularly in physiological and behavioral studies where their larger size is advantageous for surgical procedures and sample collection. The "Others" category, including models such as zebrafish and non-human primates, is essential for specialized research areas where specific biological pathways or closer physiological approximation to humans is required, though their use is more targeted and often subject to greater scrutiny. |
| By Application |
|
Pharmaceutical and Biotechnology Companies represent the leading application segment, as animal models are indispensable for their core drug discovery and development pipelines. These companies rely heavily on preclinical testing to evaluate therapeutic efficacy, understand disease mechanisms, and assess safety profiles before initiating costly human clinical trials. The rigorous regulatory requirements for new drug approvals further cement the critical role of animal testing in this sector. Academic and Research Institutes form a vital second segment, focusing on fundamental biomedical research to expand the scientific understanding of diseases. Contract Research Organizations are also significant users, providing specialized testing services to clients who lack the internal capacity, thereby driving demand for standardized and high-quality animal models. |
| By End User |
|
Government and Private Research Facilities are the primary end users, often leading large-scale research initiatives with substantial funding for chronic disease and public health research. These facilities are at the forefront of developing advanced genetically modified models. Hospitals and Diagnostic Centers utilize animal models particularly for translational research, aiming to bridge the gap between laboratory findings and clinical applications for patient care. Educational Institutions are crucial for foundational research and training the next generation of scientists, though their projects may be smaller in scale compared to dedicated research centers. The collaboration between these end-user groups fosters a dynamic ecosystem that drives innovation in model development and application. |
| By Disease Area |
|
Oncology is the leading disease area for animal model testing, driven by the high global incidence of cancer and the continuous demand for novel therapeutics. Animal models are crucial for studying tumor biology, metastasis, and the efficacy of new chemotherapeutic agents and immunotherapies. Neurology represents another major segment, with models being essential for researching complex disorders like Alzheimer's, Parkinson's, and epilepsy. Infectious disease research has seen sustained demand, particularly highlighted during global health crises, for vaccine and antiviral development. Metabolic disorders, including diabetes and obesity, also constitute a significant segment where animal models help elucidate disease pathways and test interventions, reflecting the broad therapeutic areas that depend on these preclinical tools. |
| By Service Type |
|
Contract Research Services lead this segment, as many organizations outsource complex in vivo studies to specialized providers to leverage their expertise, infrastructure, and ensure regulatory compliance. This service type is critical for efficient drug development cycles. Breeding and Model Production is a foundational service, ensuring a consistent supply of high-quality, genetically defined animals. Genetic Testing and Characterization services are increasingly vital for validating the genetic integrity of models, especially with the rise of complex genetically engineered strains. Cryopreservation services support long-term storage of valuable genetic lines, safeguarding research investments and enabling the sharing of models across the global scientific community, thus enhancing research reproducibility and collaboration. |
Global Leaders, Niche Specialists, and Regional Dynamics
The global Animal Model for Testing market is characterized by a moderately concentrated competitive landscape, with the top four manufacturers accounting for approximately 45% of the market share. Charles River Laboratories stands as the undeniable global leader, leveraging its extensive portfolio of research models and services, global breeding facility network, and strong support for preclinical drug development. It is closely followed by established players like Envigo and Taconic Biosciences, which possess significant expertise in providing high-quality, genetically defined rodent models. The market structure is heavily influenced by the dominance of rodent models, particularly mice, which constitute over 60% of the market, driven by their genetic malleability and physiological relevance to human disease. These leading companies cater primarily to the large pharmaceutical and biotechnology sector, which is the largest application segment, requiring robust and reliable preclinical data for regulatory submissions.
Beyond the market leaders, a diverse array of significant players occupies important niches. The Jackson Laboratory is a critical non-profit entity renowned for its vast repository of genetically engineered mouse models and genomic resources, serving the academic and research community extensively. Companies like Crown Biosciences and GenOway have carved out strong positions with specialized offerings in oncology and genetically engineered models, respectively. The competitive field also includes prominent contract research organizations (CROs) such as Syngene International and Pharmaron, which integrate animal model services into broader drug discovery and development workflows. Regional specialists are also key, with companies like Shanghai SLAC and Janvier Labs strengthening the supply chain in the rapidly growing Asia-Pacific and European markets. These players compete on factors including model specificity, pathogen-free status, genetic quality, technical support services, and breeding capacity.
List of Key Animal Model for Testing Companies ProfiledEnvigo
Crown Biosciences
Shanghai SLAC
Shangghai Modelorg
Syngene International
Psychogenics
Pharmaron
Pharmalegacy
Vitalstar Biotechnology
JANVIER LABS
The global Animal Model for Testing market is on a trajectory of consistent growth, valued at US$ 2382 million in 2024 and projected to reach US$ 3513 million by 2031, representing a compound annual growth rate (CAGR) of 5.8%. This expansion is fundamentally driven by the heightened demand for reliable preclinical data across the pharmaceutical and biotechnology sectors. Animal models are indispensable for understanding disease mechanisms, evaluating the safety and efficacy of new therapies, and securing regulatory approvals before human clinical trials commence. The continuous increase in research into chronic diseases, rare conditions, and infectious diseases solidifies their critical role in the biomedical research ecosystem.
Other TrendsAdvancements in Genetic Engineering
A key trend shaping the market is the advancement in genetic engineering technologies, which enables the creation of more precise and disease-specific animal models. These sophisticated models, particularly in fields like oncology, neurology, and immunology, offer greater predictive value for human responses. This trend is accelerated by strong collaborations between academic institutions and industry players, supported by government funding initiatives aimed at accelerating drug discovery and development processes.
Regional and Segment DynamicsGeographically, North America is the largest market, holding approximately 40% of the global share, followed closely by Europe and the Asia-Pacific region, which together account for over 50%. In terms of product types, mice dominate the market, constituting over 60% of the segment due to their genetic similarity to humans and well-characterized biology. The primary end-users are Pharmaceutical and Biotechnology Companies, which leverage these models extensively, followed by Academic and Research Institutes that form the foundation of basic and applied research.
Navigating Ethical and Scientific Challenges
Despite their utility, the industry faces significant headwinds. Intensifying ethical concerns regarding animal welfare are leading to stricter regulatory guidelines and increased scrutiny. Concurrently, the high cost and complexity of developing and maintaining specialized models present accessibility challenges, particularly for smaller research entities. Furthermore, a persistent scientific limitation is that animal models do not always perfectly predict human biological responses, which can lead to inefficiencies in drug development pipelines. These challenges are fostering a parallel growth in alternative testing methods, though animal models remain irreplaceable for comprehensive in vivo studies.
Regional Analysis: Animal Model for Testing MarketEurope
Europe represents a highly significant and mature market for animal models, characterized by a strong collaborative network across its member states. The region benefits from harmonized regulations, such as the EU Directive on the protection of animals used for scientific purposes, which standardizes practices and ensures high ethical standards, thereby fostering a reliable research environment. Major markets like the United Kingdom, Germany, and France host world-class academic research institutions and a thriving pharmaceutical industry that demands a wide array of animal models. There is a notable focus on developing and utilizing models for regulatory safety testing and advanced therapeutic areas, supported by significant public funding initiatives like the Horizon Europe program. The presence of large contract research organizations further solidifies the region's position, offering comprehensive preclinical services that rely heavily on animal models.
Asia-Pacific
The Asia-Pacific region is the fastest-growing market for animal models, driven by rapidly expanding pharmaceutical and biotechnology sectors, particularly in China, Japan, and India. This growth is fueled by increasing government investments in biomedical research, a rising burden of chronic diseases, and the outsourcing of preclinical research by multinational corporations seeking cost-effective solutions. Countries like China are investing heavily in building state-of-the-art animal facilities and developing their own genetically engineered models, aiming to reduce dependency on Western suppliers. Japan has a long-standing reputation for high-quality scientific research and maintains a strong demand for sophisticated models. The region's market dynamics are shaped by a combination of cost advantages, growing scientific expertise, and an increasingly supportive regulatory landscape, making it a critical area for future market expansion.
South America
The animal model market in South America is smaller but developing, with Brazil being the most prominent player. The market growth is primarily driven by an expanding domestic pharmaceutical industry and increased government focus on scientific research and public health initiatives. Research is often concentrated in public universities and government research institutes, focusing on infectious diseases prevalent in the region and agricultural research. While the market lacks the advanced infrastructure and funding levels of North America or Europe, there is a growing recognition of the importance of preclinical research. Challenges include regulatory variability across countries and limited investment in specialized breeding facilities, but the region represents a potential growth area as its scientific capabilities continue to mature.
Middle East & Africa
The animal model market in the Middle East and Africa is nascent and fragmented, with activity concentrated in a few countries such as Israel, South Africa, and some Gulf Cooperation Council nations. Israel stands out for its advanced biotechnology sector and academic research, creating demand for sophisticated models. In the Gulf region, increasing investments in healthcare infrastructure and economic diversification strategies are beginning to foster a research environment that will require animal models. Across Africa, market development is slow, hampered by limited funding, infrastructure challenges, and pressing public health priorities. However, research focusing on region-specific diseases, such as malaria and tuberculosis, provides a foundation for niche growth in the use of animal models for testing.
This market research report offers a holistic overview of global and regional markets for the forecast period 2024-2031. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Genetic engineering advancements
Impact of precision medicine applications
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Ethical considerations and regulatory challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Academic and research institutions
Contract research organizations
Investors, consultants, and policy makers
-> Global animal model for testing market was valued at USD 2,382 million in 2024 and is projected to reach USD 3,513 million by 2031.
-> Key players include Charles River Laboratories, Envigo, Taconic Biosciences, and Jackson Laboratory, among others.
-> The market is expected to grow at a CAGR of 5.8% during the forecast period 2024-2031.
-> North America is the largest market with about 40% share, followed by Europe and Asia-Pacific.
-> Key applications include pharmaceutical R&D, academic research, and biotechnology development.
Our Clients
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates